Published on : Jun 22, 2017
Albany, New York, June 22, 2017: From the past few years, the pharmaceutical industry is undergoing a rapid transformation. Innovation, particularly the development of new products, is a crucial element of the pharmaceutical industry. At present, the vast majority of pipeline products are currently in early-stage development and are yet to demonstrate both safety and efficacy, however, the complete size of the overall pipeline indicates a steady stream of incremental and breakthrough innovation. To offer a detailed analysis of the pharmaceutical pipeline, a study titled “Innovation and Clinical Trial Tracking Factbook 2017: An Assessment of the Pharmaceutical Pipeline” has been recently published to the vast repository of Market Research Hub (MRH). Additionally, a detailed contextual analysis of the key drivers of this pipeline is provided, with an assessment of companies existing in the pipeline and historical deal value and volume.
This study is a comprehensive, granular analysis of the 25,522 products currently in the pharmaceutical industry pipeline, especially from the discovery stage through to pre-registration and then divided into therapy areas and key indications. The research that that, the market is highly research-intensive, being deeply reliant on a high level of R&D investment and a strong product pipeline to maintain growth and ensure long-term revenue generation.
Pharmaceutical companies continue to strive to bring new safe and effective drugs to market that are even better. There are some additional drugs/therapies currently in the R&D pipeline that are also hoped to improve several disease conditions. Key therapy areas focused in the report by indication includes:
- Central Nervous System
- Infectious Diseases
The prime focus of this report is placed on analysis of the development of innovative drugs, specifically first-in-class innovation. Over recent years, in addition to a rise in the yearly number of new chemical entity approvals by the FDA, the number and proportion of these approvals that were first-in-class at the time of approval have also augmented. Without successful innovation, which can be broadly defined as the market launch of novel therapeutic molecules that cost-effectively treat or cure diseases, the industry would face a substantial long-term decline in revenue, finds the study.
Oncology, central nervous system (CNS) disorders and infectious diseases account for 68% of the global pharmaceutical industry pipeline. However, with the continued focus on genomic and immunology-based clinical trial research, the future for oncologic drugs will continue to become a bit brighter every day. First and foremost, cancer drugs are king, with oncology treatments dominating both current and projected drug pipelines. Other major growth areas include immune therapies, biologics, rare-disease drugs and neurological treatments.
With the above crucial data, the research study provides readers a highly accessible reference which is useful in any pharmaceutical strategic decision-making process. The buyers will also be able to understand the contemporary role and importance of radical and incremental innovation within the various disease areas.
Click here to get more info with TOC in a PDF Format :https://www.marketresearchhub.com/enquiry.php?type=S&repid=1144779
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : email@example.com